Press Releases InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update November 14, 2023 Read More » InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 November 2, 2023 Read More » InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules October 26, 2023 Read More » InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules October 24, 2023 Read More » InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies October 24, 2023 Read More » InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update September 29, 2023 Read More » InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance September 22, 2023 Read More » InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference September 7, 2023 Read More » InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET July 21, 2023 Read More » InMed Provides Update on BayMedica Rare Cannabinoid Business July 20, 2023 Read More » InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa June 22, 2023 Read More » InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting June 1, 2023 Read More » InMed to Participate in Upcoming Virtual Investor Events May 24, 2023 Read More » InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET May 18, 2023 Read More » InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update May 15, 2023 Read More » InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa March 28, 2023 Read More » InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions March 13, 2023 Read More » InMed to Participate in Upcoming Investor Events March 7, 2023 Read More » InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update February 17, 2023 Read More » InMed Submits Form 12b-25 February 9, 2023 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update November 14, 2023 Read More »
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 November 2, 2023 Read More »
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules October 26, 2023 Read More »
InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules October 24, 2023 Read More »
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies October 24, 2023 Read More »
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update September 29, 2023 Read More »
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance September 22, 2023 Read More »
InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference September 7, 2023 Read More »
InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET July 21, 2023 Read More »
InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa June 22, 2023 Read More »
InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting June 1, 2023 Read More »
InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET May 18, 2023 Read More »
InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update May 15, 2023 Read More »
InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa March 28, 2023 Read More »
InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions March 13, 2023 Read More »
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update February 17, 2023 Read More »